MENU
+Compare
BIOGY
Stock ticker: OTC
AS OF
Aug 21 closing price
Price
$9.50
Change
-$0.28 (-2.86%)
Capitalization
1.11B

BIOGY stock forecast, quote, news & analysis

BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products... Show more

BIOGY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for BIOGY with price predictions
Sep 05, 2025

BIOGY sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for BIOGY moved above the 200-day moving average on September 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on September 05, 2025. You may want to consider a long position or call options on BIOGY as a result. In of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BIOGY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

BIOGY moved below its 50-day moving average on August 21, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BIOGY crossed bearishly below the 50-day moving average on September 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.843) is normal, around the industry mean (16.575). P/E Ratio (31.645) is within average values for comparable stocks, (74.307). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.902). BIOGY's Dividend Yield (0.075) is considerably higher than the industry average of (0.031). P/S Ratio (6.293) is also within normal values, averaging (42.680).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIOGY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOGY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

A.I.Advisor
published Dividends

BIOGY paid dividends on May 29, 2025

Biogaia AB BIOGY Stock Dividends
А dividend of $0.71 per share was paid with a record date of May 29, 2025, and an ex-dividend date of May 09, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.92B. The market cap for tickers in the group ranges from 5.57K to 67.95B. ZTS holds the highest valuation in this group at 67.95B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 86%. PCLOF experienced the highest price growth at 90%, while INNPF experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was 22% and the average quarterly volume growth was 109%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 66
Price Growth Rating: 53
SMR Rating: 83
Profit Risk Rating: 91
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
BIOGY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Kungsbroplan 3A
Phone
+46 855529300
Employees
164
Web
https://www.biogaia.se